ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1320

TAS5315, a Novel Bruton’s Tyrosine Kinase Inhibitor, Ameliorates Inflammation and Bone Erosion in Murine Model for Rheumatoid Arthritis

Yohei Yoshiga1, Fumihito Hosoi1, Satoru Iguchi1, Ryuusuke Kaneko2, Yoshinori Nakachi1, Daichi Akasaka2, Kenji Tanaka2, Kazuhiko Yonekura2, Teruhiro Utsugi2, Eiji Sasaki2 and Yoshikazu Iwasawa2, 1TAIHO PHARMACEUTICAL CO., LTD., TSUKUBA, Japan, 2TAIHO PHARMACEUTICAL CO., LTD., Tsukuba, Japan

Meeting: 2017 ACR/ARHP Annual Meeting

Date of first publication: September 18, 2017

Keywords: Animal models, BTK, inflammatory arthritis, kinase, osteoclastogenesis and rheumatoid arthritis

  • Tweet
  • Email
  • Print
Session Information

Date: Monday, November 6, 2017

Title: Rheumatoid Arthritis – Animal Models Poster II

Session Type: ACR Poster Session B

Session Time: 9:00AM-11:00AM

Background/Purpose:

The erosions of bone and cartilage are a cardinal feature of rheumatoid arthritis (RA) and associated with disease severity and poor functional outcome. Although several anti-inflammatory drugs improve symptoms of articular inflammation, they are less effective against bone erosion. The bone erosions in RA are associated with aberrant activations of osteoclasts induced by pro-inflammatory cytokines and receptor activator of nuclear factor κB ligand (RANKL). Bruton’s tyrosine kinase (BTK), which is expressed in immune cells and mature osteoclast, is reported to be a key molecule in inflammatory response and bone resorption. Thus, targeting BTK may be efficacious against not only inflammation but also bone erosion through direct regulation of activation of effector cells such as B cells, macrophages and osteoclasts in RA.

In this study, we evaluated the effect of TAS5315, a novel BTK inhibitor, on the expression of inflammatory factors from macrophages and osteoclasts activation compared with BTK inhibitor CC-292, and bone erosion by time-dependent micro-CT analysis in mouse collagen-induced arthritis (CIA).

Methods:

Kinase selectivity of TAS5315 was assessed by available kinase assay panels. The effects of TAS5315 on macrophages and osteoclasts were assessed by examining phosphorylation of BTK, expression of inflammatory factors, osteoclast differentiation and bone resorptions compared with that of BTK inhibitor CC-292. TAS5315 were orally administrated once a day for 21 consecutive days in an established mouse CIA model. Disease severity was evaluated by clinical score of paw swelling. Changes in bone mineral density (BMD) and bone erosion by TAS5315 were assessed using time-dependent micro-CT analysis.

Results:

TAS5315 selectively inhibited the enzyme activity of BTK and had less off target inhibition against other kinases. TAS5315 dose-dependently suppressed the expression of inflammatory factors (TNFα and IL-8) in macrophages. TAS5315 showed more potent efficacy against phosphorylation of BTK, osteoclastogenesis and bone resorbing activity in osteoclasts compared with CC-292. In established mouse CIA model, TAS5315 significantly ameliorated paw swelling in a dose-dependent manner and showed the anti-inflammatory effects in pathological analysis at a dose of 0.1 mg/kg. Most importantly, TAS5315 also showed repair of bone erosion and improvements of BMD from joint destruction in the initial treatment by micro-CT analysis.

These data suggests that TAS5315 indicated more potent efficacy on joint damage as well as inflammation, and also improved bone erosion in murine model for RA through direct inhibitory effects against osteoclasts function.

Conclusion:

Our study demonstrates that TAS5315 could be a promising RA therapeutic agent by improving bone erosion as well as inflammation.


Disclosure: Y. Yoshiga, None; F. Hosoi, None; S. Iguchi, None; R. Kaneko, None; Y. Nakachi, None; D. Akasaka, None; K. Tanaka, None; K. Yonekura, None; T. Utsugi, None; E. Sasaki, None; Y. Iwasawa, None.

To cite this abstract in AMA style:

Yoshiga Y, Hosoi F, Iguchi S, Kaneko R, Nakachi Y, Akasaka D, Tanaka K, Yonekura K, Utsugi T, Sasaki E, Iwasawa Y. TAS5315, a Novel Bruton’s Tyrosine Kinase Inhibitor, Ameliorates Inflammation and Bone Erosion in Murine Model for Rheumatoid Arthritis [abstract]. Arthritis Rheumatol. 2017; 69 (suppl 10). https://acrabstracts.org/abstract/tas5315-a-novel-brutons-tyrosine-kinase-inhibitor-ameliorates-inflammation-and-bone-erosion-in-murine-model-for-rheumatoid-arthritis/. Accessed .
  • Tweet
  • Email
  • Print

« Back to 2017 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/tas5315-a-novel-brutons-tyrosine-kinase-inhibitor-ameliorates-inflammation-and-bone-erosion-in-murine-model-for-rheumatoid-arthritis/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology